Caplin Point allocates over Rs 1,000 crore for expansion

Caplin Point Laboratories Limited has allocated over Rs 1,000 crore for capacity and product expansion projects expected to be completed over the next two years, financed solely through internal accruals. About 50% of the programme was nearing completion, while free cash reserves stood at Rs 1,534 crore on September 30, 2026.

How much is Caplin Point spending on expansion?

Caplin Point has set an enhanced capital expenditure budget of approximately over Rs 1,000 crore for investment projects across manufacturing and research capabilities. The company said around 50% of the investment programme was nearing completion, with the projects expected to be completed over the next two years and fully commercialised within one year after each investment is completed.

Caplin Point said the spending is intended to augment existing production capacity, widen its product range and achieve backward integration for a majority of products. Backward integration refers to producing active pharmaceutical ingredients, or APIs, used in finished formulations. The company said it would finance the full programme through internal accruals and remain net-cash positive through the investment period.

How has Caplin Point's cash flow changed during the investment period?

Caplin Point's H1 FY27 capital expenditure rose to Rs 135 crore from Rs 94 crore in H1 FY26, while free cash flow after capital expenditure declined to Rs 70 crore from Rs 160 crore. Cash flow from operations was Rs 205 crore in H1 FY27, compared with Rs 254 crore a year earlier.

The difference between the two half years was a Rs 41 crore increase in capital expenditure, alongside a Rs 49 crore reduction in cash flow from operations. Caplin Point reported Rs 1,534 crore of free cash reserves and Rs 2,967 crore of total liquid assets as of September 30, 2026, the balances management cited in describing its internal-funding capacity.

Which facilities are included in Caplin Point's expansion plan?

Caplin Point's main unfinished projects are an oncology API facility at Thervoy SIPCOT near Chennai, an oral solid dosage and dermatology facility in Puducherry, and an injectable and ophthalmic facility at Gummidipoondi. The Thervoy plant had completed civil activity and is targeted for CY27, the Puducherry project is targeted for Q1 FY28, and the Gummidipoondi project is scheduled for Q2 FY28.

The Thervoy unit is intended to make oncology APIs for existing and regulated markets, with the first drug master files, or DMFs, expected in the year following CY27 completion. A DMF is a regulatory submission containing confidential manufacturing and quality information. The Puducherry facility is designed for markets including Mexico, Brazil, the US and the European Union, and Caplin Point said it aims to expand OSD and dermatology capacity by more than two times.

Caplin Point also expects construction of the COL-II facility at Gummidipoondi to finish by August 2027. The facility is designed to house five injectable, ophthalmic and blow-fill-seal, or BFS, lines, with provision for three additional lines. The strategic project table identifies the Gummidipoondi injectable and ophthalmic project as a Q2 FY28 project for regulated markets.

What parts of Caplin Point's manufacturing programme are already completed?

Caplin Point listed three completed projects: the CP1 facility in Suthukeny, Puducherry, for lyophilised injectables and dual-chamber syringes; the general API facility upgrade in Visakhapatnam; and the oncology formulation facility at Kakkalur near Chennai. The Visakhapatnam unit has received a commercial licence, supplied its first commercial product to Caplin Point, and is expected to make its first DMF filings within FY27.

At Kakkalur, Caplin Point completed exhibit batches for four injectable and OSD products and plans submission batches for 16 products over the next 12 months for Latin American, US and European markets. The company is also undertaking due diligence on around 12 oncology abbreviated new drug applications, or ANDAs, which are approved or filed for approval, as potential acquisitions.

Caplin Point has started expanding Amaris Clinical to accommodate up to 120 beds, with completion expected by the end of FY27. The project follows pivotal bioequivalence studies for multiple OSD and softgel products from its internal research pipeline. The company said it has five dedicated research and development setups, including three approved by the Department of Scientific and Industrial Research.

What operating performance and product plans support Caplin Point's programme?

Caplin Point reported H1 FY27 total revenue of Rs 1,307 crore, up 19.1% from Rs 1,097.8 crore in H1 FY26. Earnings before interest, tax, depreciation and amortisation, or EBITDA, increased 19.8% to Rs 503.5 crore, while profit after tax rose 16.2% to Rs 361.4 crore. EBITDA margin was 38.5%, compared with 38.3% in H1 FY26.

Emerging markets accounted for 79% of H1 FY27 geographical revenue and the US represented 21%. Caplin Steriles Limited's H1 FY27 revenue mix was 82% product supply and 18% milestone plus profit share. Caplin Point also reported inventories of Rs 544 crore, with 45% held in warehouses close to customers, and receivables of 129 days as of September 30, 2026.

The company said it had invested over Rs 870 crore in manufacturing and research and development over the preceding five years using internal accruals. Research and development spending, including capital and operating expenditure, equalled 15.5% of FY26 profit after tax. Caplin Point has completed research and development for more than 90 APIs for backward integration and targets its first DMF filing by the end of FY27.

Conclusion

Caplin Point's over Rs 1,000 crore programme combines completed API and oncology formulation assets with further spending on oncology APIs, OSD, dermatology, injectables and ophthalmic products. The company is funding the programme internally while reporting Rs 1,534 crore of free cash reserves, although H1 FY27 free cash flow was Rs 70 crore against Rs 160 crore in H1 FY26 as capital expenditure rose to Rs 135 crore.

The disclosed milestones to watch are first DMF filings from Visakhapatnam within FY27, the Amaris Clinical expansion by the end of FY27, Puducherry project completion in Q1 FY28 and the Gummidipoondi project in Q2 FY28. Caplin Point also targets completion of the Thervoy oncology API facility in CY27, with its first DMFs planned in the following year.